Recent Pharmaceuticals releases

Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects

[PRESSWIRE] SEATTLE and VANCOUVER, British Columbia, Sept. 27, 2018 -- Achieve Life Sciences, Inc. (NASDAQ :ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation for cytisine.

EUROSTARS GRANTS PROJECT FUNDING FOR IMMUNOMONITOR CONSORTIUM

[PRESSWIRE] ‘s-Hertogenbosch, The Netherlands - 5 July, 2018 -- A total grant sum of EUR 2 million has been awarded to a multidisciplinary EUROSTARS consortium. The EUROSTARS project is titled "Treatment Response Monitoring for Cancer Immunotherapies Using Immune Repertoire Analysis” and named IMMUNOMONITOR.

The hidden epidemic: Worldwide, over 850 million people suffer from kidney diseases

[PRESSWIRE] Germany - 27 June, 2018 -- Kidney diseases have so far been underestimated in many respects: most people are not aware of their impaired kidney function. In general, kidney diseases are “silent diseases”, most often there are no apparent early symptoms. Many people with kidney diseases are not aware that they have been living with higher risks of cardiovascular diseases, infections, hospitalizations, and of course kidney failure which requires dialysis or transplantation.

Robotics: Changing the Face of Drug Discovery – PharmaBoardroom

 [PRESSWIRE] LONDON, June 19, 2018 -- While the automotive and electronics industries, among others, have been relatively fast in adopting robotics, pharma has been lagging behind.

Zaluvida Announces New Scientific Advisory Board

[PRESSWIRE] Boston, MA - June 12, 2018 -- Zaluvida a global life science group, announced today the formation of a Scientific Advisory Board (SAB) to inform the Human Health Research & Development department about the latest research, scientific methods, and opportunities for weight-loss management, and help further technology and product development for the company.

Vectorcide International announces MALARIA BREAKTHROUGH

[PRESSWIRE] London, United Kingdom -- 11 April, 2018 - To coincide with this month’s WORLD MALARIA DAY and THECOMMONWEALTH CONFERENCE which has malaria prevention high on the agenda, Vectorcide International Ltd www.vectorcide.co.uk - a private UK company - announces their breakthrough-coating product (containing a WHO approved active ingredient) to combat and kill the female mosquito: the carrier of diseases such as Malaria, Dengue, Zika, etc.

Grünenthal and KU Leuven Join Forces to Develop an Innovative Non-Opioid Pain Treatment

 [PRESSWIRE] AACHEN, Germany and LEUVEN, Belgium, April 9, 2018 -- Grünenthal, the Katholieke Universiteit Leuven's Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) announced today that they have entered into a research collaboration for the development of novel non-opioid drug candidates for the treatment of painful diseases with a high unmet medical need.

Karo Pharma Supports Operation Smile

 [PRESSWIRE] HUDDINGE, Sweden, March 23, 2018 -- Karo Pharma has decided to support Operation Smile with a donation of 2,5 MSEK.

PharmaBoardroom Releases 'Healthcare and Life Sciences Review Brazil 2018'

 [PRESSWIRE] LONDON, March 5, 2018 -- PharmaBoardroom today releases its new 60-page Healthcare & Life Sciences Review Brazil 2018.

Velvet Energy UK Voices Support for Yuhan's Deer Velvet Product Investment

 [PRESSWIRE] LONDON, March 2, 2018 -- New Zealand deer velvet supplier Velvet Energy UK has given its support to a multi-million dollar investment made by one of South Korea's largest pharmaceutical companies.